Reata Pharmaceuticals, Inc.

Warner-lambert Company

Abbvie Inc.

Chitase Lee

Xin Jiang

Melean Visnick

Bradley W Caprathe

Gary Louis Bolton

Xue-min Cheng

William Howard Roark

Eric Anderson

Christopher F Bender

Bharat Kalidas Trivedi

Joseph Thomas Repine

Annette Marian Doherty

Jeremy John Edmunds

Amy Mae Bunker

Andrew G Geyer

Gary Frederick Filzen

Richard William Skeean

Martha R Hotema

Gerald David Kanter

Brian Edward Kornberg

Bradley William Caprathe

Annette M Doherty

Sham Shridhar Nikam

Edward Faith Elslager

Leslie M Werbel

Daniele Marie Leonard

Kyunghye Ahn

Noe Erasga

Zachary S Sheldon

Paul C Unangst

Rolf Wagner

Allan C Krueger

Patrick Michael O'Brien

Pamela L Donner

David J Grampovnik

Hui-Ju J Chen

Howard Robin Heyman

Larry D Bratton

Jason P Shanley

Michael J Rozema

Christopher Bender

Brian Kornberg

Gary Bolton

Jason Shanley

Howard Heyman

William Roark

Allan Krueger

David Grampovnik

Pamela Donner

Hui-Ju Chen

Michael Rozema

William H Roark

Disclosed herein are compounds of the formulas: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to inhibit RORγ and/or reduce the expression of IL-17. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or autoimmune disorders.

Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other uses

Disclosed herein are compounds of the formula: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to modulate the activity of IL-17 and RORγ. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or for autoimmune disorders.

Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma

Provided are biaryl amides and coumarin-based compounds with modified sugar groups for treatment of diseases associated with heat shock protein pathway. The compounds having the following formulas, wherein variables are as defined herein. Formulae (I), (II), (III), (IV), and (V), Pharmaceutical compositions of the compounds are also provided. These biaryl amides and coumarin-based derivatives with modified sugar groups are useful for treatment and prevention of diseases and disorders, including neurological disorders, such as neurodegenerative diseases and nerve damaging disorders, for example, diabetic peripheral neuropathy.

Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway

Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.

Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators

Disclosed herein are C4 modified oleanolic acid derivatives of the formula: Formula (X) or Formula (XII), as well as analogs thereof, wherein the variables are defined herein. In addition, disclosed herein are pharmaceutical compositions of these derivatives or analogs, methods for their manufacture, and methods for their use, including for the prevention and treatment of diseases or disorders associated with overproduction of IL-17. 

C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses

Disclosed herein are compounds of the formulas: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to inhibit ROR&#x3b3; and/or reduce the expression of IL-17. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or autoimmune disorders. 

Disclosed herein are compounds of the formula: (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant inflammation modulators. In some aspects, the present disclosure provides methods wherein the compounds and composition described herein are used for the treatment of diseases and disorders associated with inflammation and cancer. 

Imidazolyl tricyclic enones as antioxidant inflammation modulators

The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein R, R, R, R, R, R, m, n, X and Y are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use for the treatment and prevention of diseases such as those associated with oxidative stress and inflammation.

Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators

This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.

Compounds that modulate PPAR activity and methods of preparation

This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.

Growing community of inventors

Ann Arbor, MI, United States of America

Chitase Lee